NRIXNurix Therapeutics, Inc.

Price: $23.59 | Today's Change: +6.60%

---

What Happened

Nurix Therapeutics, Inc. filed an 8-K with the SEC on October 13, 2026, reporting its financial results for the third quarter of fiscal year 2026 under Items 2.02 and 9.01. Revenue from contracts with customers reached $70.4 million for Q3 FY2026, a significant figure for a clinical-stage biopharmaceutical company and a sharp increase from the $12.7 million reported in Q1 FY2024, suggesting material collaboration or licensing activity has contributed to the top line. The company reported a net loss of $56.4 million (basic and diluted EPS of -$2.22) and an operating loss of $202.6 million for the quarter.

---

Why It Matters

The revenue figure of $70.4 million stands out as a meaningful milestone for a company at Nurix's stage of development. For investors, the key practical takeaway is that collaboration revenues — likely driven by partnership agreements — are providing a significant funding cushion against the substantial operating cash burn reflected in the $202.6 million operating loss. The gap between operating loss and net loss ($202.6M vs. $56.4M) suggests that non-operating items — such as investment income or other financial gains — are meaningfully offsetting operational cash consumption. This dynamic is critical for investors assessing runway: a large headline operating loss is partially mitigated by a considerably smaller net loss.

Key numbers to hold in mind:

• Revenue: $70,403,000 (Q3 FY2026)
• Net Loss: -$56,351,000 (Q3 FY2026)
• Operating Loss: -$202,571,000 (Q3 FY2026)
• EPS (Basic & Diluted): -$2.22

This follows StockWatch's initiating coverage on Nurix published on October 8, 2026, and these results represent the first formal earnings disclosure since that coverage was established.

---

Analysis

The most notable feature of this quarter is the substantial divergence between the operating loss and the net loss. An operating loss of over $200 million in a single quarter for a company of Nurix's size reflects aggressive R&D investment — consistent with the capital-intensive nature of advancing a degrader-based therapeutics pipeline through clinical development. The fact that net loss lands at roughly $56 million rather than $200 million points to either significant non-operating income (potentially from a large cash and investment portfolio generating yield) or other accounting items materially reducing the bottom-line impact. Investors should look for the accompanying financial statements filed under Item 9.01 to understand the exact composition of that gap.

The stock's +6.60% move on the day of this report indicates that the market is interpreting these results positively — the revenue figure in particular may be coming in ahead of expectations or reaffirming the value of the company's collaboration agreements.

What to watch next:

• The composition of the $70.4M in revenue — whether it is milestone payments, royalties, or research-reimbursement, as this affects its recurrence
• Cash and investment balance to gauge operational runway given the elevated operating loss
• Pipeline updates from management's commentary accompanying these results
• Whether collaboration partners are advancing their co-developed programs toward catalysts

---

Disclaimer

This report is a news and informational summary based solely on data extracted from Nurix Therapeutics' SEC filing dated October 13, 2026. It does not constitute investment advice, a solicitation to buy or sell any security, or an equity research recommendation. Readers should conduct their own due diligence and consult a qualified financial advisor before making investment decisions.

Existing Coverage

StockWatch has full coverage on NRIX, published 2026-10-08. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-10-13. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1549595/000154959526000048/nrix-20261012.htm